News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133
28 May 2024
byNatalia Reoutova
Interim results of the Italian, multicentre, open-label, phase IIIb MAURIS trial in “real-world” patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) show similar safety and efficacy to those achieved by atezolizumab plus carboplatin and etoposide in the pivotal, phase I/III IMpower133 trial.
28 May 2024

Impaired thyroid hormone sensitivity ups MACE risk in angiography patients
27 May 2024
Euthyroid patients undergoing coronary angiography who have impaired sensitivity to thyroid hormone are at increased risks of major adverse cardiovascular events (MACE) and cardiovascular death, a recent study has shown.
27 May 2024






